About the company
AbbVie, a leading pharmaceutical company, has established itself as a dominant player in the fields of immunology and oncology. With a robust portfolio and a commitment to innovation, AbbVie has become renowned for its groundbreaking therapies and medications. One of AbbVie's most notable achievements is the development of Humira, a pioneering drug that has revolutionized the treatment of various autoimmune diseases. Humira has garnered immense success and is currently a major contributor to AbbVie's profits, accounting for nearly half of the company's overall revenue. Its efficacy in treating conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis has made it a go-to treatment option for countless patients around the world. AbbVie's journey began in 2013 when it separated from Abbott, a diversified healthcare company. Spinning off from Abbott allowed AbbVie to focus solely on its pharmaceutical business, empowering them to further advance their research and development efforts in immunology and oncology. The move also provided AbbVie with the agility and flexibility necessary to evolve as an independent entity and pursue strategic initiatives. In a strategic move to bolster its product portfolio and expand into new therapeutic areas, AbbVie recently completed the acquisition of Allergan. Through this acquisition, AbbVie gained access to an extensive range of drugs related to aesthetics and women's health. This includes popular Botox and Juvederm products for cosmetic enhancements, as well as medications for addressing women's specific health needs. The addition of Allergan's portfolio not only diversifies AbbVie's offerings but also positions the company to tap into new and growing markets with significant unmet medical needs. This strategic decision aligns with AbbVie's vision of providing comprehensive healthcare solutions and improving the lives of patients around the world. AbbVie's commitment to innovation extends beyond its current product offerings. The company continues to invest heavily in research and development, aiming to bring new breakthrough therapies to market. By leveraging its expertise in immunology and oncology, AbbVie is actively working on developing novel treatments that have the potential to address unmet medical needs in devastating diseases such as cancer, multiple sclerosis, and Alzheimer's. Moreover, AbbVie actively collaborates with academic institutions, research organizations, and other biotechnology and pharmaceutical companies to foster a culture of innovation and drive scientific advancements. This collaborative approach has proven instrumental in accelerating the development of cutting-edge therapies and ensuring that patients receive the best possible care. As AbbVie looks to the future, it remains committed to its core values of patient-centricity, scientific rigor, and ethical conduct. By staying at the forefront of medical advancements and leveraging its expertise, the company strives to enhance the lives of patients, improve healthcare outcomes, and contribute to the overall well-being of society. In conclusion, AbbVie has emerged as a global leader in the pharmaceutical industry due to its strong presence in immunology and oncology. With flagship drug Humira driving its success, the recent acquisition of Allergan has added new dimensions to AbbVie's portfolio. Expanding their offerings in aesthetic and women's health, AbbVie is poised to address a wider range of medical needs. With a steadfast commitment to innovation and collaboration, AbbVie aims to continue pioneering groundbreaking therapies and making a significant impact in healthcare worldwide.
Website: https://www.abbvie.com
Data updated: June 2, 2026
